Cullinan Oncology Q2 2023: Net loss $32.2M; cash $512.1M; pipeline advances with Phase 3 start

Cullinan Therapeutics, Inc.

2023-Q2 EPS reported -$2.24

Cash and investments $512.1M as of June 30, 2023; expected runway into 2026.
Net loss $32.2M in Q2 2023 vs $58.1M in Q1 2023; R&D expenses decreased due to one-time $25M upfront in Q1.
Phase 3 REZILIENT-3 study of zipalertinib in EGFR exon20 NSCLC first-line initiated in August 2023.
CLN-619 monotherapy expansion cohorts in endometrial and cervical cancers initiated; first patient dosed in Phase 1 CLN-978 for R/R B-NHL.
IND cleared for CLN-617; Phase 1 study expected to start in H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cullinan Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Cullinan Oncology, Inc. (Nasdaq: CGEM; “Cullinan”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and announced its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Cullinan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040950

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.